Edition:
India

People: Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

14.58USD
11 Nov 2019
Change (% chg)

-- (--)
Prev Close
$14.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
118,378
52-wk High
$30.25
52-wk Low
$10.29

Silvernail, Lauren 

Mrs. Lauren P. Silvernail is Chief Financial Officer, Executive Vice President - Corporate Development of the company. She has served as the Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc. ("Revance"), a pharmaceutical research and development company, from December 2015 to May 2018 and as Revance's Chief Financial Officer and Executive Vice President, Corporate Development from March 2013 to December 2015. From 2003 to 2012, Mrs. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a pharmaceutical research and development company. From 1995 to 2003, Mrs. Silvernail served in various operating and corporate development positions with Allergan, Inc., a pharmaceutical company, including Vice President, Business Development. Prior to joining Allergan, Inc., Mrs. Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the board of directors and the audit committee of Nicox S.A. Mrs. Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.

Basic Compensation

Total Annual Compensation, USD 354,433
Restricted Stock Award, USD 673,200
Long-Term Incentive Plans, USD --
All Other, USD 2,629,260
Fiscal Year Total, USD 3,656,890

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Vikram Malik

158,901

David Moatazedi

5,794,180

Lauren Silvernail

3,656,890

Michael Jafar

3,929,160

Alejandro Sabad

--

Kurt Knab

--
As Of  31 Dec 2018